Clinical Trial Finder

Inclusion Criteria:

• - Male or female, aged 18 years and above.

• - Tumor tissue obtained on a screening consent is available.

• - Confirmed with recurrent/progressive IDH-mutant 1p/19q co-deleted Oligodendroglioma WHO grade 2 or WHO grade 3, more than 12 weeks from completion of radiation.

• - Karnofsky Performance Status ≥ 60.

• - Must be a candidate for surgery/biopsy.

• - Adequate bone marrow and organ function as defined below: - ANC ≥ 1,000/mcL.

• - Platelets ≥ 100,000/mcL.

• - Hemoglobin ≥ 9 g/dL (can be transfused) - Serum creatinine ≤ 1.5 x IULN OR Creatinine clearance by Cockcroft-Gault ≥ 60 mL/min for patients with serum creatinine > 1.5 x IULN.

• - Serum total bilirubin ≤ 1.5 x IULN OR Direct bilirubin ≤ IULN for patients with total bilirubin > 1.5 x IULN.

• - AST (SGOT) and ALT (SGPT) ≤ 3 x IULN.

• - For females of childbearing potential, negative serum pregnancy test at enrollment.

• - For women and men of childbearing potential (WOCBP) must be willing to use acceptable contraceptive methods.

Exclusion Criteria:

• - Disease progression during treatment with an anti-IDH-1 or anti IDH-2.

• - Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years.

• - Metastases detected below the tentorium or beyond the cranial vault and leptomeningeal involvement.

• - Multifocal disease.

• - Corticosteroids equivalent to ≥ 4mg dexamethasone daily.

• - HIV, Hepatitis B, or Hepatitis C seropositive.

• - Known active infection or immunosuppressive disease.

• - Autoimmune disease requiring medical management with immunosuppressant.

• - Pregnancy or lactation, due to possible adverse effects on the developing fetus or infant.

• - Treatment with another investigational drug or other intervention within 30 days prior to projected first dose of study treatment (Priming phase with TTRNA-DC).

• - Severe, active co-morbidity, defined as follows: - Unstable angina and/or congestive heart failure requiring hospitalization.

• - Transmural myocardial infarction within the last 6 months.

• - Acute bacterial or fungal infection requiring intravenous antibiotics at time of enrollment.

• - Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy.

• - Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects.

• - Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition.

The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.

• - Major medical illnesses or psychiatric impairments that, in the investigator's opinion, will prevent administration or completion of protocol therapy.

After screening consent, subjects will undergo standard of care resection or biopsy for confirmatory diagnosis of disease progression and aseptic collection of tumor material for DNA and RNA extraction and sequencing, amplification, and loading of autologous DCs. Following biopsy and confirmatory pathologic diagnosis, eligible patients will be enrolled in treatment. After surgery, patients will undergo a G-CSF mobilized pheresis to collect PBMCs for DC generation and CD34+ HSCs. Amplified tumor RNA obtained from surgically resected or biopsied specimens will be used to generate total tumor RNA-pulsed DCs (TTRNA-DCs) manufactured while patients initiate salvage chemotherapy regimen after surgery. Salvage chemotherapy with IDH1/2 inhibitor will initiate 1-2 weeks after G-CSF mobilized leukapheresis for 1-3 cycles after which, treatment cycles will be paused, and the patients will receive 3 priming TTRNA-DCs vaccines every 2 weeks and undergo a non-mobilized leukapheresis to collect vaccine-boosted lymphocytes for ex vivo T cell expansion and generation of additional TTRNA-DC vaccines. Treatment with IDH1/2 inhibitor will resume with monthly TTRNA-DC vaccines for an additional 1-3 cycles until ex vivo expanded T cells are manufactured. For ACT, patients will undergo non-myeloablative conditioning with cyclophosphamide /fludarabine. The total immunotherapy regimen will consist of up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment), a single i.v. infusion of ex vivo expanded tumor-reactive T cells, and a i.v. single infusion of autologous HSCs. The duration of treatment from enrollment to completion of DLT window is anticipated to be 7 to 9 months.

Arms

Experimental: Adoptive Cellular Therapy

All participants will receive 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment), a single i.v. infusion of ex vivo expanded tumor-reactive T cells, and a i.v. single infusion of autologous HSCs.

Interventions

Biological: - TTRNA-DC vaccines with GM-CSF

Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment

Biological: - Autologous Hematopoietic Stem cells (HSCs)

Participants will receive a single infusion of autologous CD34+ HSCs

Biological: - TTRNA-xALT

Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells

Drug: - Td vaccine

All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.